Last reviewed · How we verify
Arctuvan
Arctuvan, marketed by the University Medical Center Goettingen, holds a niche position in its therapeutic segment. The drug's key composition patent is set to expire in 2028, providing a period of market exclusivity. The primary risk is the potential increase in competition following the patent expiry.
At a glance
| Generic name | Arctuvan |
|---|---|
| Sponsor | University Medical Center Goettingen |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Reducing Antibiotic Use for Uncomplicated Urinary Tract Infection in General Practice by Treatment With Uva Ursi (UU)- a Comparative Effectiveness Trial (PHASE4)
- Observational Follow-up Study of REGATTA
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Arctuvan CI brief — competitive landscape report
- Arctuvan updates RSS · CI watch RSS
- University Medical Center Goettingen portfolio CI